title: Does spironolactone ameliorate trastuzumab-induced cardiac toxicity?
abstract: The ErbB2 receptor is a proto-oncogene associated with a poor prognosis in breast cancer. Trastuzumab, a humanized anti-ErbB2 antibody currently in clinical use, has proven to be an essential tool in the immunotherapy of breast carcinoma. Additionally, ErbB2 is involved in the growth and survival pathway of adult cardiomyocytes which accounts for the trastuzumab-induced cardiotoxicity. Moreover, in metastatic breast cancer patients treated with trastuzumab, endomyocardial biopsy documented focal vacuolar changes, pleomorphic mitochondria, myocardial cell hypertrophy, and mild interstitial fibrosis on electron microscopy without accompanying light microscopic abnormalities, a finding consistent with a reversible pattern of cardiac injury. On the other hand, aldosterone and mineralocorticoid receptor (MR) researches have experienced a revival after the discovery that aldosterone and MR are not only involved in the electrolyte and volume balance but also in the pathophysiological processes of the reno-cardiovascular system. Aldosterone has both genomic and nongenotropic effects on epidermal growth factor receptor (EGFR) expression. Genomic effect induces genomic up-regulation of the EGFR protein expression via EGFR promoter, whereas nongenotropic effect leads to the EGFR transactivation resulting in persistent pathophysiological effects including formation of extracellular matrix and myocardial hypertrophy. Spironolactone, an aldosterone receptor antagonist, is known to ameliorate the cardiac damage. The underlying mechanism for the genomic interactions seem to be the stimulation of the EGFR promoter by aldosterone-bound MR, which then dose-dependently enhances the EGFR protein levels, which may be successively inhibited by spironolactone. By the light of these findings, we hypothesize that spironolactone may ameliorate trastuzumab-induced cardiotoxicity via inhibition of transactivation of the EGFR by aldosterone and reversing myocardial hypertrophy. This issue warrants further studies.
authors.affiliation: Department of Radiation Oncology, Selcuk University, Konya, Turkey. guler.aydinyavas@gmail.com
authors.forename: Guler
authors.initials: G
authors.lastname: Yavas
authors.forename: Rengin
authors.initials: R
authors.lastname: Elsurer
authors.forename: Cagdas
authors.initials: C
authors.lastname: Yavas
authors.forename: Cagdas
authors.initials: C
authors.lastname: Elsurer
authors.forename: Ozlem
authors.initials: O
authors.lastname: Ata
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D006321:Heart / Q000187:drug effects*; D006801:Humans; D000090063:Proto-Oncogene Mas; D013148:Spironolactone / Q000627:therapeutic use*; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D013148:Spironolactone; D000068878:Trastuzumab